(HealthDay)—For patients with diabetic macular edema (DME), persistence is more likely with bevacizumab than with aflibercept or ranibizumab, according to a study published online Feb. 1 in JAMA Ophthalmology.
Feb 4, 2018
0
4
Patients with hereditary hemorrhagic telangiectasia (HHT) with severe bleeding, who were treated with intravenous bevacizumab, reported a marked reduction in nose bleeds and gastrointestinal bleeding and were able to stop ...
Jan 29, 2018
0
1
A randomised trial in 650 patients has confirmed the safety and efficacy of a new second line treatment for metastatic colorectal cancer, researchers report at the ESMO Asia 2017 Congress.
Nov 20, 2017
0
1
Doctors in the north east of England face legal action from two of the world's largest pharmaceutical companies for offering patients with a serious eye condition the choice of a safe, effective but much cheaper drug, reports ...
Nov 1, 2017
0
1
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers ...
Mar 29, 2017
0
18
The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost-effective ...
Jun 9, 2016
0
0
(HealthDay)—Bevacizumab (Avastin) used to treat retinopathy of prematurity (ROP) may be linked to serious disabilities such as cerebral palsy and hearing loss, according to a study published online March 17 in Pediatrics.
Mar 21, 2016
0
6
(HealthDay)—For patients undergoing cataract surgery, both bevacizumab and triamcinolone administered at the time of surgery correlate with improvements in visual acuity (VA), but only triamcinolone is associated with sustained ...
Mar 9, 2016
0
1
Patients with advanced cervical cancer who were at intermediate and high risk of poor outcome, as assessed by the Moore criteria, gained survival benefit from having bevacizumab added to their chemotherapy regimen while those ...
Dec 15, 2015
0
1
Patients with stage 2 or stage 3 triple-negative breast cancer (TNBC) who had a pathologic complete response (pCR) after presurgery chemotherapy had increased event-free and overall survival compared with those who had more ...
Dec 9, 2015
0
3
